News

Researchers at Weill Cornell Medicine found that partnering with local religious leaders boosted adoption of family planning methods in Tanzania.

A team at Weill Cornell Medicine has mapped the location and spatial features of blood-forming cells within human bone marrow.

In patients with severe artery blockage in the lower leg, an artery-supporting device called a resorbable scaffold is superior to angioplasty, which has been the standard treatment, according to the results of a large international clinical trial co-led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.

A drug currently in clinical trials as a cancer therapy can also stimulate pancreatic beta cells to secrete insulin, revealing a previously unknown mechanism for insulin regulation in type 2 diabetes, according to a new study by Weill Cornell Medicine investigators.

Co-led by Dr. David Artis at Weill Cornell Medicine, the Allen Discovery Center for Neuroimmune Interactions at the Icahn School of Medicine at Mount Sinai hopes to revolutionize the field of medicine with a groundbreaking project to understand how the human body senses health and disease.

Researchers at Weill Cornell Medicine have uncovered a novel route to stimulate the growth of healthy insulin-producing pancreatic beta cells in a preclinical model of diabetes. The findings hold promise for future therapeutics that will improve the lives of individuals with type 2 diabetes—a condition that affects more than half a billion people worldwide.

Researchers at Weill Cornell Medicine have demonstrated how amyloid beta, a peptide associated with Alzheimer’s disease, can interact with a protein receptor on immune cells in the brain triggering a reaction that damages blood vessels and leads to neurodegeneration. 

Researchers at Weill Cornell Medicine have led a phase 1 trial of a new drug that delivers potent radiation therapy directly and specifically to cancer cells in patients with advanced prostate cancer. The clinical trial showed that the “radiopharmaceutical” was well tolerated and demonstrated promising antitumor activity.

A surprising mechanism that makes some cancers treatment-resistant has been discovered by Weill Cornell Medicine and NewYork-Presbyterian investigators.

The Department of Emergency Medicine has made tremendous strides since 2018, when Weill Cornell Medicine elevated it to a full academic department, an achievement that underscores the department’s mission to provide exceptional patient care.

Awards, honors and achievements for the month of October.  

Ambulance-based mobile stroke units (MSU) can reach patients faster to deliver clost-busting drugs that increase the likelihood of averting strokes and complete recovery compared with standard hospital emergency care, according to researchers at Weill Cornell Medicine, NewYork-Presbyterian, UTHealth Houston, Memorial Hermann-Texas Medical Center and five other medical centers across the United States.

Certain gut-dwelling fungi flourish in severe cases of COVID-19, amplifying the excessive inflammation that drives this disease while also causing long-lasting changes in the immune system, according to a new study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.

Estrogen-based menopause hormone therapy for women in mid-life should be investigated more thoroughly as a potential strategy for preventing Alzheimer’s disease, the most common form of dementia, according to a new analysis from researchers at Weill Cornell Medicine.

Mental health crises among children and adolescents requiring emergency department care skyrocketed during the pandemic and have stayed elevated despite a return to normalcy, according to a study by Weill Cornell Medicine and NewYork-Presbyterian investigators.

In experiments of unprecedented scale, investigators at Weill Cornell Medicine and the National Institutes of Health have revealed new aspects of the complex genetics behind Type 2 diabetes.

An American Heart Association (AHA) Presidential Advisory, co-authored by a committee including the dean of Weill Cornell Medicine, outlines an ambitious plan to increase rigorous research on initiatives aimed at providing food as medicine for chronic conditions.

Dr. Lisa Newman, chief of the...

A Weill Cornell Medicine researcher has received a $610,000 grant from the Department of Defense to investigate the mechanisms causing DNA instability that potentially drives metastasis in bladder cancer.

Dr. Chenxu Zhu, an assistant professor of physiology and biophysics at Weill Cornell Medicine and a core faculty member of the New York Genome Center, has been awarded the National Institutes of Health Director’s New Innovator Award to fund an ambitious project to develop single-cell sequencing tools, known collectively as “multi-omics,” that will help track age-related changes in gene regulation programs, as well as cell decay, in brain cells from preclinical models.